close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

3.915 -0.125 (-3.09%)
Streaming Delayed Price Updated: 12:41 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
2 Growth Stocks That Could Make You Richer ↗
Discover two cutting-edge growth stocks that could revolutionize medicine and space exploration. 
Via The Motley Fool
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024 ↗
PRME stock results show that Prime Medicine missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Prime Medicine Q4 Earnings ↗
 
Via Benzinga
News headline image
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names ↗
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
News headline image
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio ↗
Alphabet may have strong insight into both company's industries. 
Via The Motley Fool
News headline image
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 ↗
Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
News headline image
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 ↗
PRME stock results show that Prime Medicine beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday! 
Via InvestorPlace
News headline image
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
2 Magnificent Growth Stocks With Room to Run ↗
These deeply undervalued growth stocks could be big winners for patient shareholders. 
Via The Motley Fool
News headline image
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging ↗
Explore short-squeeze stocks for potential surges, spotlighting investor strategies and trends that could benefit your portfolio. 
Via InvestorPlace
News headline image
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. 
Via InvestorPlace
News headline image
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Pricing of Upsized Public Offering
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today